Fly News Breaks for February 8, 2017
ADHD
Feb 8, 2017 | 11:47 EDT
As previously reported, Roth Capital analyst Michael Higgins upgraded Alcobra to Buy from Neutral after the company introduced ADAIR, or Abuse Deterrent, Amphetamine Immediate Release, to address the diversion and abuse problem with ADHD medications. With $50M in cash to start 2017, the analyst believes Alcobra is well-funded. He also raised his price target on the shares to $4 from $1.
News For ADHD From the Last 2 Days
There are no results for your query ADHD